Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
2.
Am J Transplant ; 15(7): 1958-66, 2015 Jul.
Article in English | MEDLINE | ID: mdl-25846964

ABSTRACT

An unbalance between the platelet-adhesive protein von Willebrand factor (VWF) and its cleaving protease ADAMTS13 is a risk factor for thrombosis. Here, we assessed levels and functionality of VWF and ADAMTS13 in patients undergoing off-pump lung transplantation. We analyzed plasma of 10 patients and distinguished lung transplantation-specific effects from those generally accompanying open-chest surgeries by comparing results with 11 patients undergoing off-pump coronary bypass graft (CABG) surgery. Forty healthy volunteers were included for reference values. VWF antigen levels as well as the VWF ristocetin cofactor activity/VWF antigen ratio increased during lung transplantation and after CABG surgery. An increase in VWF propeptide levels was paralleled by a decrease in ADAMTS13 activity. This was more pronounced during lung transplantation. Similarly, the capacity of plasma to support platelet aggregation under shear flow conditions in vitro was more increased during lung transplantation. The proportion of high molecular weight VWF multimers was elevated in both groups without evidence for ultra-large VWF. VWF's collagen binding activity remained unchanged. In conclusion, a hyperactive primary hemostatic system develops during lung transplantation resulting both from a pronounced (functional) increase of the VWF molecule and decrease of ADAMTS13. This may increase the risk of platelet thrombosis within the allograft.


Subject(s)
ADAM Proteins/blood , Hemostatics , Lung Diseases/surgery , Lung Transplantation/adverse effects , Thrombosis/etiology , von Willebrand Factor/metabolism , ADAMTS13 Protein , Adult , Case-Control Studies , Coronary Artery Bypass , Female , Follow-Up Studies , Graft Rejection , Graft Survival , Humans , Male , Middle Aged , Platelet Adhesiveness , Postoperative Complications , Prognosis , Risk Factors , Thrombosis/metabolism , Thrombosis/pathology
3.
Am J Transplant ; 9(5): 1189-96, 2009 May.
Article in English | MEDLINE | ID: mdl-19422343

ABSTRACT

Patients with liver disease show profound changes in their hemostatic system, which may further change during liver transplantation. We previously demonstrated that highly elevated levels of the platelet adhesive protein von Willebrand factor (VWF) in patients with cirrhosis lead to an increased VWF-dependent platelet deposition under flow as compared to healthy controls. In this study we examined VWF parameters during the course of liver transplantation. We collected serial plasma samples from 20 patients undergoing liver transplantation in which we determined plasma levels of VWF and the VWF-cleaving protease ADAMTS13. Furthermore, we performed functional tests of VWF-dependent platelet adhesion. We found persistently elevated levels of VWF during and after liver transplantation. The capacity of VWF to interact with platelets normalized during the course of transplantation, and flow-mediated VWF-dependent platelet adhesion remained at levels far exceeding those observed in healthy individuals during and after transplantation. Plasma levels of ADAMTS13 dropped during transplantation, and in four patients levels below 10% of normal were observed after reperfusion. We observed the development of a hyperreactive primary hemostatic system, as evidenced by high levels of fully functional VWF and a temporary ADAMTS13 deficiency, during liver transplantation, and speculate that these changes contribute to postoperative thrombotic complications.


Subject(s)
ADAM Proteins/blood , Liver Transplantation/adverse effects , von Willebrand Factor/metabolism , ADAM Proteins/deficiency , ADAMTS13 Protein , Adult , Aged , Aprotinin/therapeutic use , Humans , Liver Diseases/classification , Liver Diseases/surgery , Middle Aged , Placebos , Platelet Adhesiveness , Postoperative Complications/blood , Reoperation/adverse effects , Trypsin Inhibitors/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL